Success stories

The Paul Scherrer Institute PSI and the Finnish company PiBond are collaborating to commercially leverage advanced semiconductor products manufactured using EUV lithography.

PSI and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, have entered into a collaboration for the joint development of the production of a novel therapeutic radionuclide, terbium-161. In this collaboration, PSI and ITM will combine their respective technologies and expertise in the production of terbium-161, including clinical and commercial use in targeted radionuclide therapy for the treatment of cancer. The goal is to be able to offer cancer patients new and better treatment options.

Terbium-161 has been identified as a very promising therapeutic isotope for targeted radionuclide therapy in cancer due to its excellent physicochemical properties: The convincing therapeutic capabilities of terbium-161 have been demonstrated in various preclinical studies at PSI. The collaboration with ITM - a pioneer and major player in the field of radiopharmaceutical applications - aims to combine PSI's long-standing research with ITM's extensive knowledge to drive further innovation in radionuclide therapy.

With this collaboration, ITM expands its research and production portfolio alongside Lutetium-177 and Actinium-225, which are currently the most widely used medical radioisotopes for targeted radionuclide therapy and which ITM supplies to hospitals and pharmaceutical partners worldwide.

In a joint collaboration, the technology transfer centre ANAXAM, PSI and Audi Sport successfully demonstrated the potential for optimising car brakes. Neutrons from the spallation neutron source SINQ at PSI were used for this purpose. Using a jointly developed measurement method, it was now possible for the first time to look live into the brake caliper and thus sound out optimisation possibilities. For the industrial partner Audi Sport, this collaboration yields promising results.

This project is a great example of successful technology transfer and shows how PSI's large-scale research facilities and ANAXAM's expertise can optimise a well-known product and contribute to new ideas.